SCHEMBL6834291

SCHEMBL6834291

Cc1cc(-c2c(F)cccc2Cl)no1.O=C(Cl)Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
RAB9A P51151 2/20 0.47
LMNA P02545 2/20 0.46
ATM Q13315 2/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 1/20 0.45
GPBAR1 Q8TDU6 1/20 0.45
MEN1 O00255 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
ALDH1A1 P00352 1/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPT P10636 2/20 0.43
P2RX7 Q99572 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086455 0.93 L3MBTL1 (0.50) L3MBTL1RAB9ALMNAATMGLA
SCHEMBL11671866 0.90 RAB9A (0.52) L3MBTL1RAB9ALMNASMN1; SMN2KMT2A
SCHEMBL10163467 0.82 RAB9A (0.49) L3MBTL1RAB9ALMNAHTTSMN1; SMN2
SCHEMBL27534068 0.81 CHRNB2 (0.43) L3MBTL1RAB9ALMNAATMGLA
SCHEMBL10519557 0.81 MAPT (0.45) L3MBTL1LMNAATMGLAHPGD
SCHEMBL5775508 0.77 CHRNB2 (0.46) L3MBTL1RAB9ALMNAATMGLA
SCHEMBL10520665 0.76 CHRNB2 (0.44) LMNAATMGLAHPGDHTT
SCHEMBL10517986 0.75 KMT2A (0.42) LMNAATMGLAHPGDHTT
SCHEMBL5309057 0.74 NOTUM (0.51) RAB9ALMNAATMGLAHPGD
SCHEMBL30881266 0.72 LMNA (0.68) L3MBTL1LMNAATMGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 L3MBTL1 1816/4885RAB9A 1783/4885LMNA 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.